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Methods that allow high throughput identification of cellular targets of bioactive small molecules are 
invaluable assets in pharmaceutical research. They are useful in mechanism of action studies of hits 
identified via phenotypic screening. Alternatively, they may uncover ‘off-target’ proteins of 
established drugs, that may contribute to their therapeutic efficacy or unwanted side effects 
(polypharmacology). Finally, such methods also allow to identify potential novel therapeutic 
applications of existing drugs within the scope of drug repositioning projects. 
  
MAmmalian Small molecule-Protein Interaction Trap (MASPIT) is a three-hybrid system that enables 
high throughput proteome-wide screening for intracellular targets of small molecules in intact 
human cells, based on the JAK-STAT signaling pathway of the cytokine receptor (CR).[1],[2] MASPIT 
employs E. coli dihydrofolate reductase (DHFR), fused to the CR to present a methotrexate (MTX) 
fusion compound (MFC) to the intracellular environment. This allows the screening of a small 
molecule bait against a collection of chimeric prey proteins. As a result of the interaction between 
the bait and a prey protein, the JAK-STAT pathway is activated, resulting in the expression of the 
luciferase reporter gene.  
 
A conditio sine qua non for successful MASPIT analysis is the availability of appropriate synthetic 
probes.[3] Here we discuss the evaluation of two alternative chemical dimerizer approaches aimed at 
increasing the sensitivity of MASPIT.[4] To circumvent the potential limitations related to the binding 
of MTX to endogenous human DHFR, we explored trimethoprim (TMP) as an alternative prokaryote-
specific DHFR ligand.[5] MASPIT evaluation of TMP fusion compounds with tamoxifen, reversine, and 
simvastatin as model baits, resulted in dose-response curves shifted towards lower EC50 values than 
those of their MTX congeners. Furthermore, we present a scalable synthesis of a versatile TMP-azido 
reagent that displayed a similar improvement in sensitivity, possibly owing to increased membrane 
permeability relative to the MTX anchor. Applying the SNAP-tag approach[6] to introduce a covalent 
bond into the system, on the other hand, produced an inferior readout than in the MTX or TMP-tag 
based assay. Therefore, further optimization efforts so as to stabilize the ternary complex in order to 
capture the transient and possibly low-affinity bait-prey interactions, were initiated by implementing 
photoactivatable crosslinkers. 
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